No. 508, Sec. 7
6th Floor Zhongxiao E. Rd. Nangang District
Taipei 115
Taiwan
886 2 2786 6589
https://www.obipharma.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo:
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Ming-Tien Lai | Chief Scientific Officer | 7,73M | N/A | N/A |
Mr. Cheng-En Tsai | VP of Medical Department & Director | 7,38M | N/A | N/A |
Dr. Heidi Wang Ph.D. | Chief Executive Officer | N/A | N/A | N/A |
Mr. Colin Kao | CFO, Accounting Supervisor & Corporate Governance Supervisor | N/A | N/A | N/A |
Mr. Po-Jen Chang | Director of Human Resources & Administration | N/A | N/A | N/A |
Ms. Sharon Lee | Director of Public Affairs | N/A | N/A | N/A |
Mr. Kevin P. Poulos | Chief Business Officer | N/A | N/A | 1959 |
Dr. Wayne Saville M.D. | Chief Medical Officer | N/A | N/A | N/A |
Dr. Dong Xu Ph.D. | Senior Vice President of Biostatistics & Data Management | N/A | N/A | N/A |
Mr. Chun-Hung Chou | Vice President of Chemical Pharmacy and R&D Office | N/A | N/A | N/A |
OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor surface antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a Globo H monoclonal antibody; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898, OBI-998, and COVID-19 BCVax drugs. The company was founded in 2002 and is headquartered in Taipei, Taiwan.
El ISS Governance QualityScore de OBI Pharma, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.